A. Hamilton 1, A. Sharma 2, S. Inzucchi 3, J. Testani 4, A. Ofstad 5, D. Fitchett 6, M. Mattheus 7, S. Verma 8, F. Zannad 9, C. Wanner 10, B. Kraus 10, 11, 12
1 Nightingale Cardiology, Adelaide, Australia
2 McGill University Health Centre, Montreal, Québec, Canada
3 Section of Endocrinology, Yale University School of Medicine, New Haven, CT, United States of America
4 Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA
5 Boehringer Ingelheim Norway KS, Asker, Norway
6 St Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, Ontario, Canada
7 Boehringer Ingelheim Pharma GmbH & Co KG, Würzburg, Germany
8 St. Michael’s Hospital, Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada
9 Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, INSERM 1116, CHRU de Nancy, FCRIN INI-CRCT, Nancy, France
10 Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany
11 Boehringer Ingelheim International GmbH, Ingelheim, Germany
12 Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany